Under the research collaboration, InteRNA will apply its unique lentiviral-based miRNA overexpression library in multi-parametric, high-throughput screening assays to identify the biological role of individual miRNAs and novel therapeutic targets in leukemia, colon, prostate and head and neck cancer.
In addition, diagnostic miRNA profiles will be developed through next-generation sequencing, in combination with InteRNA’s proprietary small RNA bioinformatics pipeline, miR-Intess, on diverse patient sample sets provided by VU university medical center (VUmc).
Roel Schaapveld, COO of InteRNA Technologies, said: “We are very excited about the opportunity of combining profiling and functional screens based on our proprietary miRNA library in the diverse research projects. This research collaboration with investigators at several departments embedded within the Cancer Center Amsterdam at the VUmc will significantly boost our discovery programs.”